Cargando…

Anti-AT1R autoantibodies and prediction of the severity of Covid-19

The stimulation of AT1R (Angiotensin II Receptor Type 1) by Angiotensin II has, in addition to the effects on the renin-angiotensin system, also pro-inflammatory effects through stimulation of ADAM17 and subsequent production of INF-gamma and Interleukin-6. This pro-inflammatory action stimulate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Papola, Franco, Biancofiore, Veronica, Angeletti, Chiara, Grimaldi, Alessandro, Carucci, Anna Cecilia, Cofini, Vincenza, Necozione, Stefano, Rosciano, Alessia, Marinangeli, Franco, Cervelli, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577881/
https://www.ncbi.nlm.nih.gov/pubmed/34772541
http://dx.doi.org/10.1016/j.humimm.2021.10.006
_version_ 1784596153596116992
author Papola, Franco
Biancofiore, Veronica
Angeletti, Chiara
Grimaldi, Alessandro
Carucci, Anna Cecilia
Cofini, Vincenza
Necozione, Stefano
Rosciano, Alessia
Marinangeli, Franco
Cervelli, Carla
author_facet Papola, Franco
Biancofiore, Veronica
Angeletti, Chiara
Grimaldi, Alessandro
Carucci, Anna Cecilia
Cofini, Vincenza
Necozione, Stefano
Rosciano, Alessia
Marinangeli, Franco
Cervelli, Carla
author_sort Papola, Franco
collection PubMed
description The stimulation of AT1R (Angiotensin II Receptor Type 1) by Angiotensin II has, in addition to the effects on the renin-angiotensin system, also pro-inflammatory effects through stimulation of ADAM17 and subsequent production of INF-gamma and Interleukin-6. This pro-inflammatory action stimulate the cytokine storm that characterizes the most severe forms of SARS-CoV-2 infection. We studied the effect of AT1Rab on the AT1R on 74 subjects with SARS-CoV-2 infection with respiratory symptoms requiring hospitalization. We divided the patients into 2 groups: 34 with moderate and 40 with severe symptoms that required ICU admission. Hospitalized subjects showed a 50% reduction in the frequency of AT1Rab compared to healthy reference population. Of the ICU patients, 33/40 (82.5%) were AT1Rab negative and 16/33 of them (48.5%) died. All 7 patients positive for AT1Rab survived. These preliminary data seem to indicate a protective role played by AT1R autoantibodies on inflammatory activation in SARS-CoV-2 infection pathology.
format Online
Article
Text
id pubmed-8577881
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-85778812021-11-10 Anti-AT1R autoantibodies and prediction of the severity of Covid-19 Papola, Franco Biancofiore, Veronica Angeletti, Chiara Grimaldi, Alessandro Carucci, Anna Cecilia Cofini, Vincenza Necozione, Stefano Rosciano, Alessia Marinangeli, Franco Cervelli, Carla Hum Immunol Short Communication The stimulation of AT1R (Angiotensin II Receptor Type 1) by Angiotensin II has, in addition to the effects on the renin-angiotensin system, also pro-inflammatory effects through stimulation of ADAM17 and subsequent production of INF-gamma and Interleukin-6. This pro-inflammatory action stimulate the cytokine storm that characterizes the most severe forms of SARS-CoV-2 infection. We studied the effect of AT1Rab on the AT1R on 74 subjects with SARS-CoV-2 infection with respiratory symptoms requiring hospitalization. We divided the patients into 2 groups: 34 with moderate and 40 with severe symptoms that required ICU admission. Hospitalized subjects showed a 50% reduction in the frequency of AT1Rab compared to healthy reference population. Of the ICU patients, 33/40 (82.5%) were AT1Rab negative and 16/33 of them (48.5%) died. All 7 patients positive for AT1Rab survived. These preliminary data seem to indicate a protective role played by AT1R autoantibodies on inflammatory activation in SARS-CoV-2 infection pathology. American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. 2022-02 2021-11-10 /pmc/articles/PMC8577881/ /pubmed/34772541 http://dx.doi.org/10.1016/j.humimm.2021.10.006 Text en © 2021 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Papola, Franco
Biancofiore, Veronica
Angeletti, Chiara
Grimaldi, Alessandro
Carucci, Anna Cecilia
Cofini, Vincenza
Necozione, Stefano
Rosciano, Alessia
Marinangeli, Franco
Cervelli, Carla
Anti-AT1R autoantibodies and prediction of the severity of Covid-19
title Anti-AT1R autoantibodies and prediction of the severity of Covid-19
title_full Anti-AT1R autoantibodies and prediction of the severity of Covid-19
title_fullStr Anti-AT1R autoantibodies and prediction of the severity of Covid-19
title_full_unstemmed Anti-AT1R autoantibodies and prediction of the severity of Covid-19
title_short Anti-AT1R autoantibodies and prediction of the severity of Covid-19
title_sort anti-at1r autoantibodies and prediction of the severity of covid-19
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577881/
https://www.ncbi.nlm.nih.gov/pubmed/34772541
http://dx.doi.org/10.1016/j.humimm.2021.10.006
work_keys_str_mv AT papolafranco antiat1rautoantibodiesandpredictionoftheseverityofcovid19
AT biancofioreveronica antiat1rautoantibodiesandpredictionoftheseverityofcovid19
AT angelettichiara antiat1rautoantibodiesandpredictionoftheseverityofcovid19
AT grimaldialessandro antiat1rautoantibodiesandpredictionoftheseverityofcovid19
AT carucciannacecilia antiat1rautoantibodiesandpredictionoftheseverityofcovid19
AT cofinivincenza antiat1rautoantibodiesandpredictionoftheseverityofcovid19
AT necozionestefano antiat1rautoantibodiesandpredictionoftheseverityofcovid19
AT roscianoalessia antiat1rautoantibodiesandpredictionoftheseverityofcovid19
AT marinangelifranco antiat1rautoantibodiesandpredictionoftheseverityofcovid19
AT cervellicarla antiat1rautoantibodiesandpredictionoftheseverityofcovid19